5 Essential Elements For ABBV-744 in clinical trials for non-small cell lung cancer (NSCLC)
In Segment C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, members will receive ABBV-744 and ruxolitinib. Individuals will acquire treatment till illness progression or maybe the participants are not able to tolerate the study drugs.88 These preclinical studies provide paradigms for foreseeable future clinical trials in AML